Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
50
CSPCY Quote, Financials, Valuation and Earnings
Last price:
$4.97
Seasonality move
:
2.79%
Day range:
$4.80 - $4.85
52-week range:
$2.31 - $5.83
Dividend yield:
2.56%
P/E ratio:
23.23x
P/S ratio:
3.84x
P/B ratio:
16.82x
Volume:
3K
Avg. volume:
5.5K
1-year change:
99.17%
Market cap:
$13.7B
Revenue:
$4B
EPS (TTM):
$0.19
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
-- | -- | -- | -- | -- |
|
IVBXF
Innovent Biologics, Inc.
|
-- | -- | -- | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -- | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | -- | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$122.7M | -$0.42 | 17.43% | -30.7% | $43.42 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
$4.80 | -- | $13.7B | 23.23x | $0.07 | 2.56% | 3.84x |
|
IVBXF
Innovent Biologics, Inc.
|
$10.89 | -- | $18.6B | 108.69x | $0.00 | 0% | 11.47x |
|
SVA
Sinovac Biotech Ltd.
|
$6.47 | -- | $464.9M | -- | $55.00 | 0% | 1.50x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
$10.24 | -- | $20.8B | 29.93x | $0.00 | 0% | 7.73x |
|
ZLAB
Zai Lab Ltd.
|
$19.69 | $43.42 | $2.2B | -- | $0.00 | 0% | 4.78x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
1.2% | 0.343 | -- | 1.93x |
|
IVBXF
Innovent Biologics, Inc.
|
17.68% | 1.263 | -- | 2.16x |
|
SVA
Sinovac Biotech Ltd.
|
3.46% | 7.263 | 12.91% | 11.22x |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
5.93% | -0.126 | -- | 1.98x |
|
ZLAB
Zai Lab Ltd.
|
22.4% | -0.192 | 5.85% | 2.56x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
CSPCY
CSPC Pharmaceutical Group Ltd.
|
$646.8M | $205.9M | 12.94% | 12.37% | 25.7% | -- |
|
IVBXF
Innovent Biologics, Inc.
|
-- | -- | -0.6% | -0.75% | -- | -- |
|
SVA
Sinovac Biotech Ltd.
|
-- | -- | -1.02% | -1.05% | -- | -- |
|
WXXWY
WuXi Biologics (Cayman), Inc.
|
-- | -- | 7.16% | 7.53% | -- | -- |
|
ZLAB
Zai Lab Ltd.
|
$69.3M | -$48.9M | -21.74% | -26.7% | -42.05% | -$44.5M |
CSPC Pharmaceutical Group Ltd. vs. Competitors
-
Which has Higher Returns CSPCY or IVBXF?
Innovent Biologics, Inc. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of --. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat Innovent Biologics, Inc.'s return on equity of -0.75%.
Company Gross Margin Earnings Per Share Invested Capital CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B IVBXFInnovent Biologics, Inc.-- -- $2.2B -
What do Analysts Say About CSPCY or IVBXF?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Innovent Biologics, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CSPC Pharmaceutical Group Ltd. has higher upside potential than Innovent Biologics, Inc., analysts believe CSPC Pharmaceutical Group Ltd. is more attractive than Innovent Biologics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 IVBXFInnovent Biologics, Inc.0 0 0 -
Is CSPCY or IVBXF More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.549, which suggesting that the stock is 45.07% less volatile than S&P 500. In comparison Innovent Biologics, Inc. has a beta of 0.054, suggesting its less volatile than the S&P 500 by 94.576%.
-
Which is a Better Dividend Stock CSPCY or IVBXF?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.07 per share corresponding to a yield of 2.56%. Innovent Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 52% of its earnings as a dividend. Innovent Biologics, Inc. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSPCY or IVBXF?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than Innovent Biologics, Inc. quarterly revenues of --. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than Innovent Biologics, Inc.'s net income of --. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 23.23x while Innovent Biologics, Inc.'s PE ratio is 108.69x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.84x versus 11.47x for Innovent Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSPCYCSPC Pharmaceutical Group Ltd.3.84x 23.23x $964.2M $203.2M IVBXFInnovent Biologics, Inc.11.47x 108.69x -- --
-
Which has Higher Returns CSPCY or SVA?
Sinovac Biotech Ltd. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of --. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat Sinovac Biotech Ltd.'s return on equity of -1.05%.
Company Gross Margin Earnings Per Share Invested Capital CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B SVASinovac Biotech Ltd.-- -- $11.8B -
What do Analysts Say About CSPCY or SVA?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Sinovac Biotech Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that CSPC Pharmaceutical Group Ltd. has higher upside potential than Sinovac Biotech Ltd., analysts believe CSPC Pharmaceutical Group Ltd. is more attractive than Sinovac Biotech Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 SVASinovac Biotech Ltd.0 0 0 -
Is CSPCY or SVA More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.549, which suggesting that the stock is 45.07% less volatile than S&P 500. In comparison Sinovac Biotech Ltd. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.394%.
-
Which is a Better Dividend Stock CSPCY or SVA?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.07 per share corresponding to a yield of 2.56%. Sinovac Biotech Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $55.00 per share. CSPC Pharmaceutical Group Ltd. pays 52% of its earnings as a dividend. Sinovac Biotech Ltd. pays out -328.35% of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSPCY or SVA?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than Sinovac Biotech Ltd. quarterly revenues of --. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than Sinovac Biotech Ltd.'s net income of --. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 23.23x while Sinovac Biotech Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.84x versus 1.50x for Sinovac Biotech Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSPCYCSPC Pharmaceutical Group Ltd.3.84x 23.23x $964.2M $203.2M SVASinovac Biotech Ltd.1.50x -- -- --
-
Which has Higher Returns CSPCY or WXXWY?
WuXi Biologics (Cayman), Inc. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of --. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat WuXi Biologics (Cayman), Inc.'s return on equity of 7.53%.
Company Gross Margin Earnings Per Share Invested Capital CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B WXXWYWuXi Biologics (Cayman), Inc.-- -- $6.6B -
What do Analysts Say About CSPCY or WXXWY?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand WuXi Biologics (Cayman), Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that CSPC Pharmaceutical Group Ltd. has higher upside potential than WuXi Biologics (Cayman), Inc., analysts believe CSPC Pharmaceutical Group Ltd. is more attractive than WuXi Biologics (Cayman), Inc..
Company Buy Ratings Hold Ratings Sell Ratings CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 WXXWYWuXi Biologics (Cayman), Inc.0 0 0 -
Is CSPCY or WXXWY More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.549, which suggesting that the stock is 45.07% less volatile than S&P 500. In comparison WuXi Biologics (Cayman), Inc. has a beta of -0.062, suggesting its less volatile than the S&P 500 by 106.225%.
-
Which is a Better Dividend Stock CSPCY or WXXWY?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.07 per share corresponding to a yield of 2.56%. WuXi Biologics (Cayman), Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 52% of its earnings as a dividend. WuXi Biologics (Cayman), Inc. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSPCY or WXXWY?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than WuXi Biologics (Cayman), Inc. quarterly revenues of --. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than WuXi Biologics (Cayman), Inc.'s net income of --. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 23.23x while WuXi Biologics (Cayman), Inc.'s PE ratio is 29.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.84x versus 7.73x for WuXi Biologics (Cayman), Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSPCYCSPC Pharmaceutical Group Ltd.3.84x 23.23x $964.2M $203.2M WXXWYWuXi Biologics (Cayman), Inc.7.73x 29.93x -- --
-
Which has Higher Returns CSPCY or ZLAB?
Zai Lab Ltd. has a net margin of 21.07% compared to CSPC Pharmaceutical Group Ltd.'s net margin of -30.98%. CSPC Pharmaceutical Group Ltd.'s return on equity of 12.37% beat Zai Lab Ltd.'s return on equity of -26.7%.
Company Gross Margin Earnings Per Share Invested Capital CSPCYCSPC Pharmaceutical Group Ltd.67.08% $0.07 $4.7B ZLABZai Lab Ltd.59.62% -$0.33 $979.3M -
What do Analysts Say About CSPCY or ZLAB?
CSPC Pharmaceutical Group Ltd. has a consensus price target of --, signalling downside risk potential of --. On the other hand Zai Lab Ltd. has an analysts' consensus of $43.42 which suggests that it could grow by 120.52%. Given that Zai Lab Ltd. has higher upside potential than CSPC Pharmaceutical Group Ltd., analysts believe Zai Lab Ltd. is more attractive than CSPC Pharmaceutical Group Ltd..
Company Buy Ratings Hold Ratings Sell Ratings CSPCYCSPC Pharmaceutical Group Ltd.0 0 0 ZLABZai Lab Ltd.8 1 0 -
Is CSPCY or ZLAB More Risky?
CSPC Pharmaceutical Group Ltd. has a beta of 0.549, which suggesting that the stock is 45.07% less volatile than S&P 500. In comparison Zai Lab Ltd. has a beta of 0.879, suggesting its less volatile than the S&P 500 by 12.141%.
-
Which is a Better Dividend Stock CSPCY or ZLAB?
CSPC Pharmaceutical Group Ltd. has a quarterly dividend of $0.07 per share corresponding to a yield of 2.56%. Zai Lab Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CSPC Pharmaceutical Group Ltd. pays 52% of its earnings as a dividend. Zai Lab Ltd. pays out -- of its earnings as a dividend. CSPC Pharmaceutical Group Ltd.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.
-
Which has Better Financial Ratios CSPCY or ZLAB?
CSPC Pharmaceutical Group Ltd. quarterly revenues are $964.2M, which are larger than Zai Lab Ltd. quarterly revenues of $116.2M. CSPC Pharmaceutical Group Ltd.'s net income of $203.2M is higher than Zai Lab Ltd.'s net income of -$36M. Notably, CSPC Pharmaceutical Group Ltd.'s price-to-earnings ratio is 23.23x while Zai Lab Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CSPC Pharmaceutical Group Ltd. is 3.84x versus 4.78x for Zai Lab Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income CSPCYCSPC Pharmaceutical Group Ltd.3.84x 23.23x $964.2M $203.2M ZLABZai Lab Ltd.4.78x -- $116.2M -$36M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
50
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 38x
Buy
55
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
37
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
59
SEZL alert for Feb 27
Sezzle, Inc. [SEZL] is down 14.29% over the past day.
Buy
83
GCT alert for Feb 27
GigaCloud Technology, Inc. [GCT] is down 7.51% over the past day.
Buy
62
LMAT alert for Feb 27
LeMaitre Vascular, Inc. [LMAT] is down 5.73% over the past day.
